Oligometastatic Prostate Carcinoma Clinical Trials

6 recruiting

Oligometastatic Prostate Carcinoma Trials at a Glance

6 actively recruiting trials for oligometastatic prostate carcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Scottsdale, Eau Claire, and Atlanta. Lead sponsors running oligometastatic prostate carcinoma studies include Mayo Clinic, Emory University, and Istituto Oncologico Veneto IRCCS.

Browse oligometastatic prostate carcinoma trials by phase

Treatments under study

About Oligometastatic Prostate Carcinoma Clinical Trials

Looking for clinical trials for Oligometastatic Prostate Carcinoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oligometastatic Prostate Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oligometastatic Prostate Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Stage III Prostate Cancer AJCC v8Localized Prostate CarcinomaStage I Prostate Cancer AJCC v8+3 more
Mayo Clinic50 enrolled1 locationNCT06389786
Recruiting
Phase 3

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Stage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Biochemically Recurrent Prostate Carcinoma+4 more
Mayo Clinic118 enrolled6 locationsNCT06205316
Recruiting
Phase 2

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Stage IVB Prostate Cancer AJCC v8Prostate AdenocarcinomaOligometastatic Prostate Carcinoma+2 more
NRG Oncology194 enrolled239 locationsNCT05053152
Recruiting
Not Applicable

Addressing Health Literacy With a Tailored Survivorship Care Plan

Stage IVB Prostate Cancer AJCC v8Localized Prostate CarcinomaOligometastatic Prostate Carcinoma
Emory University150 enrolled3 locationsNCT06674863
Recruiting
Phase 2

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Prostate AdenocarcinomaOligometastatic Prostate Carcinoma
Mayo Clinic110 enrolled1 locationNCT06369610
Recruiting

OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate

Oligometastatic Prostate Carcinoma
Istituto Oncologico Veneto IRCCS150 enrolled12 locationsNCT06273345